Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar 24;22(3):325–337. doi: 10.1177/2472630317700346

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Society for Laboratory Automation and Screening

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — Dose-response curves from different assays performed by the PharmaFlow platform. (A) Evaluation of the therapeutic index determining the effect of cytarabine in both leukemic and residual mature lymphoid cells in an acute myeloid leukemia sample with the depletion assay. (B) Evaluation of the cytotoxic effects of compounds on CD34+ progenitor cells in NBM samples (n = 10) with the depletion assay. Each line represents the median for four approved drugs. (C, D) Evaluation of the antiproliferative (C) or cytotoxic (D) activity of idelalisib determining selectively the effects in proliferative (C) and whole-cell population (D) with the native environment proliferation assay. Panels C and D represent the median and the standard deviation (vertical error bars) in 19 chronic lymphoid leukemia samples for idelalisib.